Navigation Links
Vermillion Announces Issuance of European Patent
Date:6/2/2010

FREMONT, Calif., June 2 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Pink Sheets: VRML), a molecular diagnostics company, today announced that the European Patent Office has issued a Decision to Grant patent number 1,493,741 entitled "Use of Biomarkers for Detecting Ovarian Cancer" to the Company. The patent claims are directed to biomarker combinations for the diagnosis and management of ovarian cancer and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay.

"The granting of this patent in Europe will help support our efforts to expand our commercialization into the EU. We are actively engaged in the processes required to offer OVA1 in the EU," said Gail S. Page, Vermillion CEO and Executive Chairperson.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at www.vermillion.com.

About OVA1™

OVA1™ is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the fol
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
2. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
3. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
4. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
5. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
6. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
7. Vermillion Announces Receipt of NASDAQ Panel Decision
8. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
9. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
10. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
11. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... appointed Francois Vieillard as Sales & Marketing Director. , With more than ... will be responsible for reinforcing Tronics’ business development activities worldwide. He brings to ...
(Date:7/30/2015)... , July 30, 2015 According ... Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity ... Development, Preclinical, Clinical Trial), by End Users - Global ... is expected to reach USD 2,107.99 million by 2020 ... of 15.29%. Browse more than ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... 10, 2012  Spherix Incorporated (NASDAQ: SPEX ... in diabetes, metabolic syndrome and atherosclerosis, and providers ... supplement, biotechnology and pharmaceutical companies – would like ... will host a conference call to provide a ...
... Florida have developed a novel technique that may give ... pathogens associated with inflammatory bowel disease, including Crohn,s disease. ... used for detection of other microbes that have challenged ... tissue and are able to reprogram cells to successfully ...
... Syndax Pharmaceuticals, Inc. , a clinical-stage epigenetics oncology ... Texas MD Anderson Cancer Center Department of Breast ... combining Syndax,s lead product entinostat with lapatinib ditosylate ... relapsed metastatic breast cancer previously treated with trastuzumab ...
Cached Biology Technology:Reminder: Spherix to Hold Business Update Conference Call April 11 at 1:00 p.m. Eastern Time 2Reminder: Spherix to Hold Business Update Conference Call April 11 at 1:00 p.m. Eastern Time 3UCF scientists use nanotechnology to hunt for hidden pathogens 2Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 2Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 3
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... led by Lauren Cole, a public health graduate student, ... and Director of the Epidemiology Program at LSU Health ... head and neck cancer has risen at sites associated ... increase among middle-aged white men. At the same time, ...
... developed a new method to detect proteins associated with longevity, ... longer than others. The team looked at the genome ... evolve in connection with the longevity of a species. ... damage, evolves and mutates in a non-random way in species ...
... This press release is available in German . ... a complex process during which different signalling proteins interact with ... VEGF and the Notch signalling pathway both play important roles ... its receptor, VEGFR2, while the Notch signalling pathway acts like ...
Cached Biology News:LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men 2Study suggests why some animals live longer 2Culprit behind unchecked angiogenesis identified 2
... Dideoxycytidine is a cytidine analog that has been ... Immunogen: Chemical / Small Molecule ... specificity of the ddC antiserum was determined by ... to moles of ddC analog at the 50% ...
... The Jouan MSC series of ... comfortable working conditions and certification to ... automatic regulation ensures that the cabinets ... working conditions. Natural lighting, low noise ...
... Multidizer is designed with a variety of ... - all in one unit. Shake, rock, ... operating compartments allow for hybridization and blotting ... , The upper chamber uses a ...
... the SPD series takes the 'Classic' series ... The SPD121P SpeedVac comes equipped with a ... preventing samples from freezing; and allowing runs ... preset level., Standard features on the SPD121P ...
Biology Products: